{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:53:52Z","timestamp":1740142432382,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Braz J Microbiol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s42770-023-01141-9","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T01:02:12Z","timestamp":1697158932000},"page":"2817-2826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of antibiotic combinations in an experimental sepsis model with Pseudomonas aeruginosa"],"prefix":"10.1007","volume":"54","author":[{"given":"Zerrin","family":"Aktas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nese","family":"Sonmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6722-141X","authenticated-orcid":false,"given":"Lutfiye","family":"Oksuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozden","family":"Boral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halim","family":"Issever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oral","family":"Oncul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"issue":"2","key":"1141_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/sur.2017.278","volume":"19","author":"NLM Sepsis","year":"2018","unstructured":"Sepsis NLM (2018) (2018) Definitions and guideline changes. Surg Infect 19(2):117\u2013125. https:\/\/doi.org\/10.1089\/sur.2017.278","journal-title":"Surg Infect"},{"issue":"1","key":"1141_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13054-018-2048-3","volume":"22","author":"JA Kempker","year":"2018","unstructured":"Kempker JA, Wan HE, Martin GS (2018) Sepsis is a preventable public health problem. Crit Care 22(1):116. https:\/\/doi.org\/10.1186\/s13054-018-2048-3","journal-title":"Crit Care"},{"issue":"13","key":"1141_CR3","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/jama.2017.13836)","volume":"318","author":"C Rhee","year":"2017","unstructured":"Rhee C, Dantes R, Epstein L et al (2017) Incidence and trends of sepsis in US hospitals using clinical vs claims data 2009\u20132014. JAMA 318(13):1241\u201349. https:\/\/doi.org\/10.1001\/jama.2017.13836)","journal-title":"JAMA"},{"key":"1141_CR4","doi-asserted-by":"publisher","unstructured":"Wu W, Jin Y, Bai F, Jin S (2015) Pseudomonas aeruginosa. In: Tang YW, Sussman M, Liu D, Ian Poxton, Schwartzman J (eds) Molecular medical microbiology. Academic Press, New York, pp.753\u201367. https:\/\/doi.org\/10.1016\/B978-0-12-397169-2.00041-X","DOI":"10.1016\/B978-0-12-397169-2.00041-X"},{"issue":"9","key":"1141_CR5","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1128\/AAC.00750-12","volume":"56","author":"L Morata","year":"2012","unstructured":"Morata L, Cobos-Trigueros N, Mart\u00ednez JA et al (2012) Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 56(9):4833\u201337. https:\/\/doi.org\/10.1128\/AAC.00750-12","journal-title":"Antimicrob Agents Chemother"},{"key":"1141_CR6","doi-asserted-by":"publisher","first-page":"212527","DOI":"10.7573\/dic.212527","volume":"7","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Vena A, Croxatto A, Righi E, Guery B (2018) How to manage Pseudomonas aeruginosa infections. Drugs Context 7:212527. https:\/\/doi.org\/10.7573\/dic.212527","journal-title":"Drugs Context"},{"issue":"20\u201321","key":"1141_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3238\/arztebl.2018.0345","volume":"115","author":"M Fritzenwanker","year":"2018","unstructured":"Fritzenwanker M, Imirzalioglu C, Herold S, Wagenlehner FM, Zimmer K-P, Chakraborty T (2018) Treatment options for carbapenem-resistant Gram-negative infections. Dtsch \u00c4rztebl Int 115(20\u201321):345\u2013352. https:\/\/doi.org\/10.3238\/arztebl.2018.0345","journal-title":"Dtsch \u00c4rztebl Int"},{"issue":"4","key":"1141_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jgar.2015.09.001","volume":"3","author":"B Ozbek","year":"2015","unstructured":"Ozbek B, Mataraci Kara E, Er S, Ozdamar M, Yilmaz M (2015) In vitro activities of colistin, tigecycline and tobramycin, alone or in combination, against carbapenem-resistant Enterobacteriaceae strains. J Glob Antimicrob Res 3(4):278\u2013282. https:\/\/doi.org\/10.1016\/j.jgar.2015.09.001","journal-title":"J Glob Antimicrob Res"},{"issue":"1","key":"1141_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jac\/dkw377","volume":"72","author":"O Zusman","year":"2017","unstructured":"Zusman O, Altunin S, Koppel F, Benattar YD, Gedik H, Paul M (2017) Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother 72(1):29\u201339. https:\/\/doi.org\/10.1093\/jac\/dkw377","journal-title":"J Antimicrob Chemother"},{"key":"1141_CR10","volume-title":"Time-kill assay. Clinical microbiology handsbook","author":"LM Koeth","year":"2016","unstructured":"Koeth LM (2016) Time-kill assay. Clinical microbiology handsbook, 4th edn. ASM Press, Washington","edition":"4"},{"key":"1141_CR11","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1586\/14787210.2013.846215","volume":"12","author":"JG Kmeid","year":"2013","unstructured":"Kmeid JG, Youssef MM, Kanafani ZA, Kanj SS (2013) Combination therapy for Gram-negative bacteria: what is the evidence? Expert Rev Anti Infect Ther 12:1355\u20131362. https:\/\/doi.org\/10.1586\/14787210.2013.846215","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1141_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/1471-2334-12-308","volume":"12","author":"S-Y Park","year":"2012","unstructured":"Park S-Y, Park HJ, Moon SM et al (2012) Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. BMC Infect Dis 12:308. https:\/\/doi.org\/10.1186\/1471-2334-12-308","journal-title":"BMC Infect Dis"},{"issue":"2","key":"1141_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1128\/CMR.00068-15","volume":"29","author":"ME Falagas","year":"2016","unstructured":"Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ (2016) Fosfomycin. Clin Microbiol Rev 29(2):321\u2013347. https:\/\/doi.org\/10.1128\/CMR.00068-15","journal-title":"Clin Microbiol Rev"},{"key":"1141_CR14","unstructured":"Clinical and Laboratory Standards Institute- CLSI (2012) Methods for dilution antimicrobial susceptibility tests f or bacteria that grow aerobically; approved st andard\u2014ninth edition. CLSI document M07-A9. Wayne, PA. Available at: file:\/\/\/C:\/Users\/domain\/Downloads\/03-CLSI-M07-A9\u20132012%20(1).pdf. Accessed January 2023.https:\/\/clsi.org"},{"key":"1141_CR15","unstructured":"The European Committee on Antimicrobial Susceptibility Testing - EUCAST. Rationale Documents from EUCAST (2013) Available from: https:\/\/www.eucast.org\/publications-and-documents\/rd. Accessed Mar 2023"},{"key":"1141_CR16","unstructured":"The European Committee on Antimicrobial Susceptibility Testing\u2014EUCAST. MIC and zone diameter distributions and ECOFFs Antimicrobial wild type distributions of microorganisms 2018 [cited 2023 January 5, 2023]; Available from: https:\/\/www.eucast.org\/mic_and_zone_distributions_and_ecoffs"},{"issue":"10","key":"1141_CR17","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1128\/aac.00822-15","volume":"59","author":"M D\u00edez-Aguilar","year":"2015","unstructured":"D\u00edez-Aguilar M, Morosini MI, Tedim AP, Rodriguez I, Aktas Z, Canton R (2015) Antimicrobial activity of fosfomycin-tobramycin combination against Pseudomonas aeruginosa isolates assessed by time-kill assays and mutant prevention concentrations. Antimicrob Agents Chemother 59(10):6039\u20136045. https:\/\/doi.org\/10.1128\/aac.00822-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1141_CR18","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ijantimicag.2015.08.012","volume":"46","author":"EB Hirsch","year":"2015","unstructured":"Hirsch EB, Raux BR, Zucchi BC, Kim Y, McCoy C, Kirby JE, Wright SB, Eliopoulos GM (2015) Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates. Int J Antimicrob Agents 46(6):642\u2013647. https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.08.012","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"1141_CR19","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1128\/AAC.02048-13","volume":"58","author":"LV Perdigao-Neto","year":"2014","unstructured":"Perdigao-Neto LV, Oliveira MS, Rizek CF, Carrilho CMDM, Costa SF, Levin AS (2014) Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods. Antimicrob Agents Chemother 58(3):1763\u20131767. https:\/\/doi.org\/10.1128\/AAC.02048-13","journal-title":"Antimicrob Agents Chemother"},{"key":"1141_CR20","unstructured":"Rodr\u00edguez-Gasc\u00f3n A, Canut-Blasco A (2019) Deciphering pharmacokinetics and pharmacodynamics of fosfomycin. Rev Esp Quimioter 32(Supply 1):19\u201324 (PMID: 31131588)"},{"key":"1141_CR21","unstructured":"World Health Organization. Antimicrobial resistance surveillance in Europe 2022\u20132020 data. Available at: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-surveillance-europe-2022-2020-data. Accessed January 2023."},{"issue":"6","key":"1141_CR22","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.7754\/clin.lab.2023.23031","volume":"69","author":"L Oksuz","year":"2023","unstructured":"Oksuz L, Altay G (2023) Aktas Z (2023) Trends of antibiotic resistance in multidrug-resistant pathogens from blood cultures in a four-year period: a single center experience. Clin Lab 69(6):1302\u20131312. https:\/\/doi.org\/10.7754\/clin.lab.2023.23031","journal-title":"Clin Lab"},{"issue":"2","key":"1141_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.diagmicrobio.2018.08.010","volume":"93","author":"RK Flamm","year":"2019","unstructured":"Flamm RK, Rhomberg PR, Watters AA, Sweeney K, Ellis-Grosse EJ, Shortridge D (2019) Activity of fosfomycin when tested against US contemporary bacterial isolates. Diagn Microb Infect Dis 93(2):143\u201346. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.08.010","journal-title":"Diagn Microb Infect Dis"},{"issue":"11","key":"1141_CR24","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1093\/jac\/dkv2215","volume":"70","author":"CC Walsh","year":"2015","unstructured":"Walsh CC, McIntosh MP, Peleg AY, Kirkpatrick CM, Bergen PJ (2015) In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 70(11):3042\u20133050. https:\/\/doi.org\/10.1093\/jac\/dkv2215","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1141_CR25","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/jac\/dkw115","volume":"71","author":"CC Walsh","year":"2016","unstructured":"Walsh CC, Landersdorfer CB, McIntosh MP et al (2016) Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. J Antimicrob Chemother 71(8):2218\u20132229. https:\/\/doi.org\/10.1093\/jac\/dkw115","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1141_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000048585","volume":"48","author":"BS Kocazeybek","year":"2002","unstructured":"Kocazeybek BS, Arabaci U, Erenturk S, Akdur H (2002) Investigation of various antibiotic combinations using the E-Test method in multiresistant Pseudomonas aeruginosa strains. Chemotherapy 48(1):31\u201335. https:\/\/doi.org\/10.1159\/000048585","journal-title":"Chemotherapy"},{"issue":"4","key":"1141_CR27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.5578\/mb.70087","volume":"54","author":"B Erdal","year":"2020","unstructured":"Erdal B, Yalinay M, Elmas C, Yazici GN (2020) Investigation of pseudomonas aeruginosa biofilm formation and quorum sensing genes in piperacillin\/tazobactam and ciprofloxacin sub-minimal inhibitory concentrations. Mikrobiyol Bul 54(4):547\u2013558. https:\/\/doi.org\/10.5578\/mb.70087","journal-title":"Mikrobiyol Bul"},{"issue":"2","key":"1141_CR28","doi-asserted-by":"publisher","first-page":"a025262","DOI":"10.1101\/cshperspect.a025262","volume":"7","author":"LL Silver","year":"2017","unstructured":"Silver LL (2017) Fosfomycin: mechanism and resistance. Cold Spring Harb Perspect Med 7(2):a025262. https:\/\/doi.org\/10.1101\/cshperspect.a025262","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"1141_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1590\/0037-8682-0012-2013","volume":"46","author":"DAFS Lima","year":"2013","unstructured":"Lima DAFS, Nascimento MMP, Vitali LH, Martinez R (2013) In vitro activity of antimicrobial combinations against multidrug-resistant Pseudomonas aeruginosa. Rev Soc Bras Med Trop 46(3):299\u2013303. https:\/\/doi.org\/10.1590\/0037-8682-0012-2013","journal-title":"Rev Soc Bras Med Trop"},{"key":"1141_CR30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10096-011-1360-5","volume":"31","author":"G Samonis","year":"2012","unstructured":"Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME (2012) Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 31:695\u2013701. https:\/\/doi.org\/10.1007\/s10096-011-1360-5","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1141_CR31","doi-asserted-by":"publisher","first-page":"e13132","DOI":"10.1111\/cmi.13132","volume":"22","author":"LL Guennec","year":"2020","unstructured":"Guennec LL, Coureuil M, Nassif X, Bourdoulous S (2020) Strategies used by bacterial pathogens to cross the blood\u2013brain barrier. Cellular Microbiol 22:e13132. https:\/\/doi.org\/10.1111\/cmi.13132","journal-title":"Cellular Microbiol"},{"issue":"4","key":"1141_CR32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jmii.2014.08.019","volume":"49","author":"TI Lin","year":"2016","unstructured":"Lin TI, Huang YF, Liu PY, Chou CA, Chen YS, Chen YY, Hsieh KS, Chen YS (2016) Pseudomonas aeruginosa infective endocarditis in patients who do not use intravenous drugs: analysis of risk factors and treatment outcomes. J Microbiol Immun Infect 49(4):516\u2013522. https:\/\/doi.org\/10.1016\/j.jmii.2014.08.019","journal-title":"J Microbiol Immun Infect"},{"issue":"5","key":"1141_CR33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/jac\/dkq070)","volume":"65","author":"V Matzi","year":"2010","unstructured":"Matzi V, Lindenmann J, Porubsky, et al (2010) Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 65(5):995\u2013998. https:\/\/doi.org\/10.1093\/jac\/dkq070)","journal-title":"J Antimicrob Chemother"},{"key":"1141_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jgar.2019.04.012)","volume":"18","author":"MM Montero","year":"2019","unstructured":"Montero MM, Ochoa SD, L\u00f3pez-Causap\u00e9 C et al (2019) Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones. J Glob Antimicrob Resist 18:37\u201344. https:\/\/doi.org\/10.1016\/j.jgar.2019.04.012)","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"1141_CR35","doi-asserted-by":"publisher","first-page":"e02025","DOI":"10.1128\/AAC.02025-16.)","volume":"61","author":"Y-W Lin","year":"2017","unstructured":"Lin Y-W, Zhou QT, Cheah S-E et al (2017) Pharmacokinetics\/pharmacodynamics of pulmonary delivery of colistin against Pseudomonas aeruginosa in a mouse lung infection model. Antimicrob Agents Chemother 61(3):e02025-e2116. https:\/\/doi.org\/10.1128\/AAC.02025-16.)","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1141_CR36","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/jac\/dkp282","volume":"64","author":"DL MacLeod","year":"2009","unstructured":"MacLeod DL, Barker LM, Sutherland JL et al (2009) Antibacterial activities of a fosfomycin\/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 64(4):829\u2013836. https:\/\/doi.org\/10.1093\/jac\/dkp282","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1141_CR37","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1128\/AAC.05958-11","volume":"56","author":"DL MacLeod","year":"2012","unstructured":"MacLeod DL, Velayudhan J, Kenney TF et al (2012) Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother 56(3):1529\u20131538. https:\/\/doi.org\/10.1128\/AAC.05958-11","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1141_CR38","doi-asserted-by":"publisher","first-page":"e00031","DOI":"10.1128\/CMR.00031-19","volume":"32","author":"JP Horcajada","year":"2019","unstructured":"Horcajada JP, Montero M, Oliver A et al (2019) Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 32(4):e00031-e119. https:\/\/doi.org\/10.1128\/CMR.00031-19","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"1141_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4161\/viru.26083","volume":"5","author":"MP Fink","year":"2014","unstructured":"Fink MP (2014) Animal models of sepsis Virulence 5(1):143\u2013153. https:\/\/doi.org\/10.4161\/viru.26083","journal-title":"Animal models of sepsis Virulence"},{"issue":"2","key":"1141_CR40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000341640","volume":"80","author":"MRN Celes","year":"2013","unstructured":"Celes MRN, Prado CM, Rossi MA (2013) Sepsis: going to the heart of the matter. Pathobiology 80(2):70\u201386. https:\/\/doi.org\/10.1159\/000341640","journal-title":"Pathobiology"},{"issue":"5","key":"1141_CR41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1179\/1973947813Y.0000000143","volume":"26","author":"H Demiraslan","year":"2014","unstructured":"Demiraslan H, Dinc G, Ahmed SS et al (2014) Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline\/colistin combination. J Chemother 26(5):276\u2013281. https:\/\/doi.org\/10.1179\/1973947813Y.0000000143","journal-title":"J Chemother"},{"issue":"11","key":"1141_CR42","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1128\/AAC.05028-11","volume":"55","author":"PJ Bergen","year":"2011","unstructured":"Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, Paterson DL, LiJ NRL (2011) Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 55(11):5134\u20135142. https:\/\/doi.org\/10.1128\/AAC.05028-11","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Brazilian Journal of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-023-01141-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42770-023-01141-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-023-01141-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T03:18:12Z","timestamp":1701400692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42770-023-01141-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1007\/s42770-023-01141-9","relation":{},"ISSN":["1517-8382","1678-4405"],"issn-type":[{"type":"print","value":"1517-8382"},{"type":"electronic","value":"1678-4405"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"6 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out following the ethical values specified in the Declaration of Helsinki and was approved by the Istanbul University Animal Experiments Local Ethics Committee (Ethical Approval Number: 2013\/129).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}